[Clinical studies of piperacillin in the field of obstetrics and gynecology].
We studied piperacillin (PIPC) clinically to evaluate its utility and safety, and obtained the following results. PIPC was given at a daily dose of 1 approximately 4 g for 3 approximately 10 days by bolus injection or dripping infusion to 18 patients with various infections in the field of obstetrics and gynecology. Four of 5 cases with intrauterine infection, 2 of 3 cases with focus infection of uterine cancer, 2 cases with perinatal intrauterine infection, 2 of 6 cases with adnexal infection and 2 cases with vulvar infection proved to respond effectively. The overall efficacy rate was 66.7%. No side effect or abnormal laboratory findings were observed except for 1 case with rash.
D000328:Adult; D000368:Aged; D004716:Endometritis / Q000188:drug therapy; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008875:Middle Aged; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D010406:Penicillins / Q000494:pharmacology / Q000627:therapeutic use*; D010878:Piperacillin; D013290:Streptococcal Infections / Q000188:drug therapy; D013297:Streptococcus pyogenes / Q000187:drug effects
D010406:Penicillins; D010878:Piperacillin